Johnson & Johnson's Caplyta Meets Primary Endpoints in Bipolar Mania Clinical Trial
Johnson & Johnson (JNJ) announced that its second late-stage pivotal trial for the atypical antipsychotic Caplyta successfully met both primary and key secondary endpoints. The study focused on adults experiencing manic episodes associated with bipolar I disorder, demonstrating the efficacy of the once-daily therapy. The successful results from this clinical trial represent a significant milestone for J&J's neuropsychiatry pipeline. By meeting these critical regulatory benchmarks, the company strengthens its position in the mental health therapeutic market and moves closer to potential expanded indications for Caplyta.
Tickers: $JNJ
Topics: bipolar disorder clinical trials drug development FDA approval pathway
Read the full article at Seeking Alpha
Part of the story Merck's Efinopegdutide Meets Primary Endpoint in Phase 2b MASH Clinical Trial (2 articles)